Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes

✍ Scribed by Taylor, Alison ;Ezquerra, Mario ;Bagri, Gurjog ;Yip, Agustin ;Goumidi, Louisa ;Cottel, Dominique ;Easton, Douglas ;Evans, John Grimley ;Xuereb, John ;Cairns, Nigel J. ;Amouyel, Philippe ;Chartier-Harlin, Marie-Christine ;Brayne, Carol ;Rubinsztein, David C.

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 85 KB
• Volume: 105
• Category: Article
• ISSN: 0148-7299
• DOI: 10.1002/ajmg.10044

✦ Synopsis

Abstract

Hypertension has been implicated as a risk factor for Alzheimer disease (AD) and dementia in epidemiological studies of humans. It is thus possible that there are common genetic determinants for hypertension and AD. Epidemiological, clinical, and experimental data suggest that the renin‐angiotensin‐aldosterone system is a critical regulator of blood pressure. The presence of an __Mbo__I site in an RFLP in the renin gene and the Thr at the Met/Thr polymorphism at codon 235 (M235T) of the angiotensinogen gene have been reported to be associated with hypertension. These variants were studied in autopsy‐confirmed AD cases and matched controls from the U.K. While no association was detected with the renin polymorphism, a weak deleterious effect was observed in cases homozygous for the angiotensinogen Thr allele. However, this association was not observed in a French cohort of clinically diagnosed AD cases and controls, suggesting that the initial observation was a type I error. Thus, these polymorphisms are unlikely to be associated with AD risk. © 2001 Wiley‐Liss, Inc.